Best RTSM and IRT systems for clinical trials

Compare features

Compare 8 RTSM and IRT systems across randomization, trial supply, build speed, integrations, compliance evidence and track record. None of the eight vendors publishes prices, so plan on a quote for each study. Use the sourced feature notes to discuss your protocol and supply requirements with vendors.

Best forSponsors and CROs choosing a randomization and trial supply management (RTSM, also called IRT) system for interventional trials.

Updated Nov 12, 20268 tools compared

What are RTSM and IRT?

RTSM means randomization and trial supply management. It assigns participants to treatment groups and coordinates the study-drug supply. IRT, or interactive response technology, is a related term commonly used for the systems that run these workflows.

Background: Medidata randomization and trial supply overview

What this software typically does

  • Assign treatment using the study’s randomization rules
  • Manage study-drug inventory and resupply
  • Track dispensing while protecting treatment blinding
Compare features

Compare product features

See documented feature support at a glance. Select a symbol for the explanation and source. Double checks indicate documented extra capabilities; unknown does not mean unavailable.

Products are not ranked. Table order is chosen for each guide and does not indicate a recommendation.

Select a symbol to read its evidence and source. Scroll sideways for all features.

Documented feature support for each product. Symbols describe individual features, not overall product ratings.
SoftwareRandomization and blindingTrial supply managementStudy build speed and mid-study changesIntegrations and platformCompliance and security evidenceTrack record
Prancer RTSM

Extended support

Named methods include variable blocks and minimization with blinding protection.

Extended support means: Named allocation methods include minimization or dynamic allocation.

4G names stratification, cohort-specific logic, variable blocks and minimization, with versioned logic that protects blinding and handles re-randomization.

Source

Extended support

Predictive resupply, scenario modeling and direct-to-patient shipping are stated.

Extended support means: Supply forecasting and direct-to-patient delivery (shipping or dispensing) are both documented.

Prancer handles dispensing and resupply with buffer-to-predictive forecasting and 4C Supply scenario modeling; direct-to-patient shipping was added in April 2020 (4G blog).

Source

Supported

A build timeline and changes protecting study progress are stated; uninterrupted live use is not explicit.

Supported means: Study setup or post-go-live study changes are described.

4G says its NLP-based build takes under four weeks, with specification sign-off to go-live in as little as 13 calendar days, and changes made without impacting study progress.

Source

Supported

Connections to trial systems establish base support; a public API reference was not found.

Supported means: Integration or data exchange with another system or application is described.

4G documents connections to EDC, CTMS, depot and logistics systems and data warehouses, but has no EDC or eCOA of its own and we found no public API reference.

Source

Supported

Trial standards and a dated SOC report period are stated; public report access is not established.

Supported means: Relevant trial compliance or security controls are stated, with their scope identified.

The trust center reports a SOC 2 Type 2 report for the 12 months ending 31 August 2026 and states compliance with 21 CFR Part 11 and EU Annex 11.

Source

Supported

Study adoption is reported worldwide, but no country count is given.

Supported means: Published product or wider-platform adoption, or a named clinical-research deployment.

4G says it has evolved to support more than a thousand studies worldwide.

Source
Almac

Supported

Adaptive designs and blinding protection establish base support; allocation methods are not named.

Supported means: Randomization or blinding workflows are stated.

Almac describes simple to complex adaptive designs with enrollment caps, cohorts and blinding protection, but does not name allocation methods.

Source

Extended support

Resupply and SupplyWise forecasting combine with documented direct-to-patient workflows.

Extended support means: Supply forecasting and direct-to-patient delivery (shipping or dispensing) are both documented.

IXRS 3 documents resupply strategy, expiry and depot management, Almac's SupplyWise integrates demand forecasting with the IRT, and an Almac datasheet (Clinical Leader, August 2025) describes direct-to-patient workflows.

Source

Supported

Visual study build is described; a build timeline and mid-study change process are not published.

Supported means: Study setup or post-go-live study changes are described.

Almac describes a controlled-agile build with visual requirements tools, but publishes no build timeline or mid-study change process.

Source

Extended support

EDC/CTMS connectors are documented with REST and SOAP integrations.

Extended support means: Integration with a clinical-trial application plus an API for integration are both stated.

Almac lists pre-built connectors and REST, SOAP and secure file integrations with EDC, CTMS, clinical supplies and central labs, but has no EDC or eCOA of its own.

Source

Supported

The Part 11 statement is limited to IXRS University training; ISO/SOC evidence was not found.

Supported means: Relevant trial compliance or security controls are stated, with their scope identified.

Almac states its IXRS University training module is validated and 21 CFR Part 11 compliant; we found no named ISO 27001 or SOC 2 attestation for Clinical Technologies.

Source

Extended support

Product-specific trial and patient figures are reported across a stated country count.

Extended support means: Product-specific study, customer, institution, site or participant figures plus a published country count establish international use.

Almac's media kit reports 2,000 clinical trials and over 2 million patients on IXRS, in more than 85 countries (undated kit).

Source
Endpoint

Supported

Adaptive protocol support establishes base support; allocation methods are not named.

Supported means: Randomization or blinding workflows are stated.

Endpoint cites complex protocols, dosing strategies, adaptive designs and patient rollover, but its product pages do not name specific allocation methods.

Source

Extended support

Direct-to-patient delivery is stated alongside Bluefin supply forecasting.

Extended support means: Supply forecasting and direct-to-patient delivery (shipping or dispensing) are both documented.

Elosity adds direct-to-patient delivery, site-to-site shipments, central pharmacy workflows and pooling, and Endpoint's Bluefin product provides AI-driven supply forecasting.

Source

Extended support

A study-setup timeline and version-tracked changes without interrupting live studies are stated.

Extended support means: Study setup is described, and post-go-live changes explicitly avoid interrupting live study use.

Elosity claims a 2-6 week study setup and version-tracked quick changes without interrupting live studies; PULSE offers 20+ self-service modules.

Source

Extended support

API-based integrations connect RTSM with EDC, eCOA, eConsent and CTMS.

Extended support means: Integration with a clinical-trial application plus an API for integration are both stated.

Endpoint describes pre-built, API-based integrations with EDC, eCOA, eConsent and CTMS, but names no specific systems and has no EDC or eCOA of its own.

Source

Supported

A SOC attestation establishes base security evidence; product-specific trial controls and public report access are not established.

Supported means: Relevant trial compliance or security controls are stated, with their scope identified.

Endpoint holds a SOC 2 Type II attestation (Prescient Assurance); we found no product-specific Part 11 or Annex 11 statement beyond a general FAQ.

Source

Extended support

Product-specific study and patient adoption is reported across a stated country count.

Extended support means: Product-specific study, customer, institution, site or participant figures plus a published country count establish international use.

Endpoint reports 2,000+ studies, 1M+ patients and 90+ countries.

Source
Medidata RTSM

Extended support

Named methods include permuted blocks and dynamic allocation with stratification.

Extended support means: Named allocation methods include minimization or dynamic allocation.

A Medidata fact sheet lists pre-validated permuted block and dynamic allocation, stratification, cohort management, titration and a randomization simulator (fact sheet dated May 2019).

Source

Extended support

Predictive supply schemes and forecasting are documented alongside direct-to-patient shipments.

Extended support means: Supply forecasting and direct-to-patient delivery (shipping or dispensing) are both documented.

The current fact sheet documents buffer and predictive supply schemes, forecasting that simulates future patient needs, direct-to-patient shipments and drug pooling across studies.

Source

Supported

A build timeline and live amendments are stated, but little-to-no downtime permits some interruption.

Supported means: Study setup or post-go-live study changes are described.

Medidata states a 2-3 week study build, and Edit Live Design allows post-go-live changes for protocol amendments (the 2024 fact sheet adds 'little to no downtime').

Source

Supported

Rave and depot integrations establish base support; an API is not stated in this note.

Supported means: Integration or data exchange with another system or application is described.

RTSM is unified with Rave EDC on the Medidata Platform and uses a pre-validated two-way integration with large depot vendors.

Source

Supported

A certificate and audit are listed, but public document access is not established; trial statements require customer login.

Supported means: Relevant trial compliance or security controls are stated, with their scope identified.

Medidata lists an ISO 27001:2022 certificate and a SOC 2+ Type II audit, and says its position statements cover 21 CFR Part 11 and EU Annex 11 (the statements sit behind a customer login).

Source

Extended support

Product-specific monthly patient usage is reported alongside a stated country count.

Extended support means: Product-specific study, customer, institution, site or participant figures plus a published country count establish international use.

The RTSM page cites 124 countries supported and about 16,000 patients a month.

Source
Signant

Supported

Randomization and emergency unblinding are stated; allocation methods are not named.

Supported means: Randomization or blinding workflows are stated.

Signant mentions emergency unblinding and support for any protocol design or randomization scheme, but does not name allocation methods.

Source

Extended support

Direct-to-patient dispensing combines with a Forecasting and Planning module.

Extended support means: Supply forecasting and direct-to-patient delivery (shipping or dispensing) are both documented.

Signant documents direct-to-patient dispensing, cross-study pooling, shelf-life optimization and a Forecasting and Planning module in SmartSignals Supplies.

Source

Supported

The timeline ends at UAT; amendment impact assessment does not establish uninterrupted live changes.

Supported means: Study setup or post-go-live study changes are described.

Signant states new builds in as little as three weeks from requirements sign-off to UAT and AI-assisted impact assessment for amendments, but does not claim changes without downtime.

Source

Extended support

Native eCOA and third-party EDC connections are stated alongside RTSM APIs.

Extended support means: Integration with a clinical-trial application plus an API for integration are both stated.

The RTSM connects to Signant's own eCOA and supplies software, third-party EDC and manufacturing systems, and offers RTSM APIs for near real-time data.

Source

Supported

Part 11 is stated for supply inventory history; ISO/SOC attestation evidence was not found.

Supported means: Relevant trial compliance or security controls are stated, with their scope identified.

Signant states that its SmartSignals Supplies inventory transaction history is 21 CFR Part 11 compliant; we found no named ISO 27001 or SOC 2 attestation.

Source

Extended support

Product-specific study and customer adoption is reported across a stated country count.

Extended support means: Product-specific study, customer, institution, site or participant figures plus a published country count establish international use.

A March 2026 Signant brochure reports 2,000+ RTSM studies in 90+ countries and 600+ sponsors and CROs as customers.

Source
Suvoda RTSM

Supported

Adaptive and stratified randomization are stated; minimization or dynamic allocation is not named.

Supported means: Randomization or blinding workflows are stated.

Suvoda lists adaptive randomization, stratification, cohort and dose management and blinding management, but its public pages do not name minimization or dynamic allocation.

Source

Extended support

Drug forecasting and direct-to-patient shipping are both named.

Extended support means: Supply forecasting and direct-to-patient delivery (shipping or dispensing) are both documented.

The RTSM page lists drug supply forecasting, direct-to-patient shipping, temperature excursion management, and accountability, returns and destruction.

Source

Supported

The UAT timeline concerns preliminary testing; permissioned changes do not establish uninterrupted live use.

Supported means: Study setup or post-go-live study changes are described.

Suvoda states kickoff to UAT in as little as two weeks (footnoted as preliminary testing), and permissioned users can make common post-go-live changes without a change order.

Source

Extended support

Pre-built EDC API integrations and a REST API are stated.

Extended support means: Integration with a clinical-trial application plus an API for integration are both stated.

Suvoda reports integrations with more than 100 eClinical systems, standardized pre-built API integrations with top EDC providers and a REST API.

Source

Supported

RTSM trial controls and an annual SOC audit are stated; public report access is not established.

Supported means: Relevant trial compliance or security controls are stated, with their scope identified.

Suvoda says its RTSM adheres to 21 CFR Part 11 and that it maintains SOC 2 Type 2 compliance; its certifications page confirms an annual SOC 2 Type 2 audit for RTSM.

Source

Extended support

Product-specific trial adoption is reported across a stated country count.

Extended support means: Product-specific study, customer, institution, site or participant figures plus a published country count establish international use.

Suvoda reports 6,000+ trials and 115+ countries supported.

Source
Veeva

Extended support

Named methods explicitly include dynamic allocation and minimization.

Extended support means: Named allocation methods include minimization or dynamic allocation.

Veeva lists static, stratified, dynamic/minimization, forced and adaptive schemas, re-randomization, capping and sentinel dosing.

Source

Supported

Predictive resupply establishes base support; direct-to-patient shipping is not documented.

Supported means: Drug inventory, dispensing, shipping or resupply workflows are documented.

Veeva documents threshold, predictive and just-in-time resupply with expiry buffers and accountability, but no direct-to-patient shipping or separate forecasting tool.

Source

Supported

Mid-study cohort and limit changes are stated; an initial build timeline and uninterrupted changes are not established.

Supported means: Study setup or post-go-live study changes are described.

Authorized users can switch on cohorts and change limits mid-study, and Veeva says design-change amendments often take days rather than weeks; no initial build timeline is published.

Source

Supported

Native and external trial-system connections establish base support; an API is not stated in this note.

Supported means: Integration or data exchange with another system or application is described.

Productized connections send data to Veeva EDC, eCOA and DQS and take site data from Veeva CTMS, and the brief cites third-party EDC and shipping-provider connections.

Source

Supported

Vendor security audits are listed; RTSM-specific trial controls and public document access are not established.

Supported means: Relevant trial compliance or security controls are stated, with their scope identified.

Veeva's trust page lists ISO 27001 audits and a SOC 2 Type II report, but we found no RTSM-specific Part 11 or Annex 11 statement.

Source

Supported

An enterprise-standard selection provides base track-record evidence; product-specific adoption figures are not published.

Supported means: Published product or wider-platform adoption, or a named clinical-research deployment.

Veeva reports that a top-20 biopharma selected Veeva RTSM as its enterprise standard (fiscal 2026); no total study or customer count for RTSM is published.

Source
YPrime IRT

Extended support

Named methods include permuted blocks, dynamic allocation and minimization.

Extended support means: Named allocation methods include minimization or dynamic allocation.

YPrime names permuted block and stratified randomization, dynamic allocation and minimization (Pocock and Simon), stratum caps and conditional re-randomization.

Source

Supported

Inventory and resupply establish base support; forecasting and direct-to-patient shipping are not described.

Supported means: Drug inventory, dispensing, shipping or resupply workflows are documented.

The IRT page covers inventory, orders, resupply, kit replacement and depot rules, but does not describe supply forecasting or direct-to-patient shipping.

Source

Supported

Build timelines and immediately effective routine changes are stated; uninterrupted live use is not explicit.

Supported means: Study setup or post-go-live study changes are described.

YPrime cites build to go-live in under four weeks for an early-phase oncology trial, about a week for the simplest designs, and self-service routine changes that take effect immediately.

Source

Supported

Trial-system integrations establish base support; an API is not stated in this note.

Supported means: Integration or data exchange with another system or application is described.

YPrime documents integrations with EDC, eCOA, eConsent, CTMS, labs, distribution systems and data lakes, and runs its own eCOA.

Source

Supported

Trial and privacy standards are stated; ISO/SOC attestation evidence was not found.

Supported means: Relevant trial compliance or security controls are stated, with their scope identified.

YPrime's trust page lists 21 CFR Part 11, GDPR and HIPAA compliance, but we found no ISO 27001 or SOC 2 attestation.

Source

Supported

Supported means: Published product or wider-platform adoption, or a named clinical-research deployment.

YPrime reports 55,000+ sites and 300,000+ patients supported and 20+ years of IRT work, but publishes no study count.

Source
  • Supported
  • Extended support
  • Not available
  • Unknown
What do the checks mean for this guide?

Every product uses the same definitions. Double checks indicate documented extra capabilities in that column; they do not indicate an overall winner. Unknown means the available sources do not establish support.

Randomization and blinding
Supported: Randomization or blinding workflows are stated.
Extended support: Named allocation methods include minimization or dynamic allocation.
Trial supply management
Supported: Drug inventory, dispensing, shipping or resupply workflows are documented.
Extended support: Supply forecasting and direct-to-patient delivery (shipping or dispensing) are both documented.
Study build speed and mid-study changes
Supported: Study setup or post-go-live study changes are described.
Extended support: Study setup is described, and post-go-live changes explicitly avoid interrupting live study use.
Integrations and platform
Supported: Integration or data exchange with another system or application is described.
Extended support: Integration with a clinical-trial application plus an API for integration are both stated.
Compliance and security evidence
Supported: Relevant trial compliance or security controls are stated, with their scope identified.
Extended support: Relevant trial controls and a publicly accessible ISO certificate or SOC audit report covering the product or vendor are documented.
Track record
Supported: Published product or wider-platform adoption, or a named clinical-research deployment.
Extended support: Product-specific study, customer, institution, site or participant figures plus a published country count establish international use.
Read the detailed feature comparison

Select a feature label for its details and source. Scroll sideways for all features.

Feature statements for each product, with public sources. Products appear in editorial order.
SoftwareRandomization and blindingTrial supply managementStudy build speed and mid-study changesIntegrations and platformCompliance and security evidenceTrack record
Prancer RTSM
Stratification, variable blocks + minimization — details and source

4G names stratification, cohort-specific logic, variable blocks and minimization, with versioned logic that protects blinding and handles re-randomization.

Source
Predictive resupply + modeling + direct-to-patient — details and source

Prancer handles dispensing and resupply with buffer-to-predictive forecasting and 4C Supply scenario modeling; direct-to-patient shipping was added in April 2020 (4G blog).

Source
Under 4 weeks; changes protect progress (vendor claim) — details and source

4G says its NLP-based build takes under four weeks, with specification sign-off to go-live in as little as 13 calendar days, and changes made without impacting study progress.

Source
EDC/CTMS/logistics links; no public API reference — details and source

4G documents connections to EDC, CTMS, depot and logistics systems and data warehouses, but has no EDC or eCOA of its own and we found no public API reference.

Source
SOC 2 Type 2 (2026); Part 11/Annex 11 stated — details and source

The trust center reports a SOC 2 Type 2 report for the 12 months ending 31 August 2026 and states compliance with 21 CFR Part 11 and EU Annex 11.

Source
1,000+ studies worldwide (vendor claim) — details and source

4G says it has evolved to support more than a thousand studies worldwide.

Source
Almac
Adaptive designs; allocation methods not named — details and source

Almac describes simple to complex adaptive designs with enrollment caps, cohorts and blinding protection, but does not name allocation methods.

Source
Resupply + SupplyWise forecasting + direct-to-patient — details and source

IXRS 3 documents resupply strategy, expiry and depot management, Almac's SupplyWise integrates demand forecasting with the IRT, and an Almac datasheet (Clinical Leader, August 2025) describes direct-to-patient workflows.

Source
Visual agile build; timeline/changes not published — details and source

Almac describes a controlled-agile build with visual requirements tools, but publishes no build timeline or mid-study change process.

Source
REST/SOAP/file links; no native EDC/eCOA — details and source

Almac lists pre-built connectors and REST, SOAP and secure file integrations with EDC, CTMS, clinical supplies and central labs, but has no EDC or eCOA of its own.

Source
Training module Part 11 stated; ISO/SOC not found — details and source

Almac states its IXRS University training module is validated and 21 CFR Part 11 compliant; we found no named ISO 27001 or SOC 2 attestation for Clinical Technologies.

Source
2,000 trials, 85+ countries (undated vendor kit) — details and source

Almac's media kit reports 2,000 clinical trials and over 2 million patients on IXRS, in more than 85 countries (undated kit).

Source
Endpoint
Adaptive designs; allocation methods not named — details and source

Endpoint cites complex protocols, dosing strategies, adaptive designs and patient rollover, but its product pages do not name specific allocation methods.

Source
Direct-to-patient + pooling + Bluefin forecasting — details and source

Elosity adds direct-to-patient delivery, site-to-site shipments, central pharmacy workflows and pooling, and Endpoint's Bluefin product provides AI-driven supply forecasting.

Source
2–6 weeks; uninterrupted changes (vendor claim) — details and source

Elosity claims a 2-6 week study setup and version-tracked quick changes without interrupting live studies; PULSE offers 20+ self-service modules.

Source
API-based suite links; specific systems not named — details and source

Endpoint describes pre-built, API-based integrations with EDC, eCOA, eConsent and CTMS, but names no specific systems and has no EDC or eCOA of its own.

Source
SOC 2 Type II; product-specific Part 11 not found — details and source

Endpoint holds a SOC 2 Type II attestation (Prescient Assurance); we found no product-specific Part 11 or Annex 11 statement beyond a general FAQ.

Source
2,000+ studies, 90+ countries (vendor claim) — details and source

Endpoint reports 2,000+ studies, 1M+ patients and 90+ countries.

Source
Medidata RTSM
Block/dynamic allocation + simulator (2019 sheet) — details and source

A Medidata fact sheet lists pre-validated permuted block and dynamic allocation, stratification, cohort management, titration and a randomization simulator (fact sheet dated May 2019).

Source
Predictive forecasting + direct-to-patient/pooling — details and source

The current fact sheet documents buffer and predictive supply schemes, forecasting that simulates future patient needs, direct-to-patient shipments and drug pooling across studies.

Source
2–3 weeks; little/no downtime (vendor claim) — details and source

Medidata states a 2-3 week study build, and Edit Live Design allows post-go-live changes for protocol amendments (the 2024 fact sheet adds 'little to no downtime').

Source
Unified Rave EDC + two-way depot integrations — details and source

RTSM is unified with Rave EDC on the Medidata Platform and uses a pre-validated two-way integration with large depot vendors.

Source
ISO/SOC listed; Part 11 statements behind login — details and source

Medidata lists an ISO 27001:2022 certificate and a SOC 2+ Type II audit, and says its position statements cover 21 CFR Part 11 and EU Annex 11 (the statements sit behind a customer login).

Source
124 countries, ~16K patients/month (vendor claim) — details and source

The RTSM page cites 124 countries supported and about 16,000 patients a month.

Source
Signant
Emergency unblinding; allocation methods not named — details and source

Signant mentions emergency unblinding and support for any protocol design or randomization scheme, but does not name allocation methods.

Source
Direct-to-patient + pooling + forecasting — details and source

Signant documents direct-to-patient dispensing, cross-study pooling, shelf-life optimization and a Forecasting and Planning module in SmartSignals Supplies.

Source
From 3 weeks to UAT (vendor claim); downtime not stated — details and source

Signant states new builds in as little as three weeks from requirements sign-off to UAT and AI-assisted impact assessment for amendments, but does not claim changes without downtime.

Source
Native eCOA/supply + EDC links + RTSM APIs — details and source

The RTSM connects to Signant's own eCOA and supplies software, third-party EDC and manufacturing systems, and offers RTSM APIs for near real-time data.

Source
Part 11 inventory history stated; ISO/SOC not found — details and source

Signant states that its SmartSignals Supplies inventory transaction history is 21 CFR Part 11 compliant; we found no named ISO 27001 or SOC 2 attestation.

Source
2,000+ RTSM studies, 90+ countries (2026 brochure) — details and source

A March 2026 Signant brochure reports 2,000+ RTSM studies in 90+ countries and 600+ sponsors and CROs as customers.

Source
Suvoda RTSM
Adaptive/stratified randomization + cohort/dose rules — details and source

Suvoda lists adaptive randomization, stratification, cohort and dose management and blinding management, but its public pages do not name minimization or dynamic allocation.

Source
Forecasting + direct-to-patient + temperature tracking — details and source

The RTSM page lists drug supply forecasting, direct-to-patient shipping, temperature excursion management, and accountability, returns and destruction.

Source
UAT from 2 weeks (preliminary testing; vendor claim) — details and source

Suvoda states kickoff to UAT in as little as two weeks (footnoted as preliminary testing), and permissioned users can make common post-go-live changes without a change order.

Source
100+ eClinical links + EDC connectors + REST API — details and source

Suvoda reports integrations with more than 100 eClinical systems, standardized pre-built API integrations with top EDC providers and a REST API.

Source
Part 11 stated; annual RTSM SOC 2 Type 2 audit — details and source

Suvoda says its RTSM adheres to 21 CFR Part 11 and that it maintains SOC 2 Type 2 compliance; its certifications page confirms an annual SOC 2 Type 2 audit for RTSM.

Source
6,000+ trials, 115+ countries (vendor claim) — details and source

Suvoda reports 6,000+ trials and 115+ countries supported.

Source
Veeva
Static, dynamic/minimization + adaptive schemas — details and source

Veeva lists static, stratified, dynamic/minimization, forced and adaptive schemas, re-randomization, capping and sentinel dosing.

Source
Predictive/JIT resupply; direct-to-patient undocumented — details and source

Veeva documents threshold, predictive and just-in-time resupply with expiry buffers and accountability, but no direct-to-patient shipping or separate forecasting tool.

Source
Cohort/limit changes; initial build time unpublished — details and source

Authorized users can switch on cohorts and change limits mid-study, and Veeva says design-change amendments often take days rather than weeks; no initial build timeline is published.

Source
Native EDC/eCOA/DQS/CTMS + external links — details and source

Productized connections send data to Veeva EDC, eCOA and DQS and take site data from Veeva CTMS, and the brief cites third-party EDC and shipping-provider connections.

Source
ISO/SOC listed; RTSM-specific Part 11 not found — details and source

Veeva's trust page lists ISO 27001 audits and a SOC 2 Type II report, but we found no RTSM-specific Part 11 or Annex 11 statement.

Source
Enterprise client example; RTSM totals not published — details and source

Veeva reports that a top-20 biopharma selected Veeva RTSM as its enterprise standard (fiscal 2026); no total study or customer count for RTSM is published.

Source
YPrime IRT
Permuted blocks, dynamic allocation + minimization — details and source

YPrime names permuted block and stratified randomization, dynamic allocation and minimization (Pocock and Simon), stratum caps and conditional re-randomization.

Source
Resupply; forecasting/direct-to-patient not described — details and source

The IRT page covers inventory, orders, resupply, kit replacement and depot rules, but does not describe supply forecasting or direct-to-patient shipping.

Source
Under 4 weeks in case study (vendor claim) — details and source

YPrime cites build to go-live in under four weeks for an early-phase oncology trial, about a week for the simplest designs, and self-service routine changes that take effect immediately.

Source
Native eCOA + EDC/CTMS/lab/distribution links — details and source

YPrime documents integrations with EDC, eCOA, eConsent, CTMS, labs, distribution systems and data lakes, and runs its own eCOA.

Source
Part 11/HIPAA/GDPR stated; ISO/SOC not found — details and source

YPrime's trust page lists 21 CFR Part 11, GDPR and HIPAA compliance, but we found no ISO 27001 or SOC 2 attestation.

Source
55K+ sites, 300K+ patients; study count unpublished — details and source

YPrime reports 55,000+ sites and 300,000+ patients supported and 20+ years of IRT work, but publishes no study count.

Source

The short list

Products in editorial order
  • Prancer RTSMStudy fit: sponsors and CROs with complex dosing or adaptive designs who want an RTSM specialist with supply forecasting
  • Almac IXRS 3Study fit: sponsors who also use Almac for clinical packaging and distribution and want IRT, forecasting and logistics from one group
  • Endpoint Clinical RTSMStudy fit: sponsors who want an RTSM specialist with self-service study changes and central pharmacy workflows
  • Medidata RTSMStudy fit: sponsors already on Rave EDC who want randomization and supply in the same system
  • Signant SmartSignals RTSMStudy fit: sponsors who want RTSM, supply forecasting and eCOA from one vendor
  • Suvoda RTSMStudy fit: oncology, CNS and rare disease sponsors who want IRT alongside eCOA, eConsent and patient payments on one platform
  • Veeva RTSMStudy fit: sponsors standardizing on the Veeva Clinical Platform who want RTSM connected to Veeva EDC, eCOA and CTMS
  • YPrime IRTStudy fit: sponsors with complex randomization schemes, including minimization, who may also use YPrime eCOA

Compare at a glance

SoftwareSecurity certificationsBuild timePricing model
Prancer RTSM

Needs facts

Under four weeks; spec sign-off to go-live in as little as 13 calendar days (vendor figure)

Source

Not published

Source
Almac IXRS 3

Needs facts

Needs facts

Not published

Source
Endpoint Clinical RTSM

SOC 2 Type II, attested by Prescient Assurance

Source

2-6 week study setup on Elosity (vendor figure)

Source

Not published

Source
Medidata RTSM

ISO 27001:2022, ISO 27017:2015, ISO 27018:2019, ISO 27701:2019, SOC 2+ Type II

Source

Needs facts

No prices published; the Patient Cloud service descriptions publish contract terms (devices on a rental basis, caps on fee adjustments, early-termination fees)

Source
Signant SmartSignals RTSM

Needs facts

As little as three weeks from requirements sign-off to UAT (vendor figure)

Source

Not published

Source
Suvoda RTSM

Annual SOC 2 Type 2 audit for RTSM, eCOA and eConsent; ISO 27001 for Greenphire payments products

Source

Kickoff to UAT in as little as two weeks (footnoted as preliminary testing)

Source

Not published

Source
Veeva RTSM

ISO 27001, ISO 27017, ISO 27018 controls audited yearly; SOC 2 Type II report; ISO 9001

Source

Needs facts

Not published

Source
YPrime IRT

ISO 27001 certification in progress (target 2027)

Source

Under four weeks for an early-phase oncology trial; about a week for the simplest designs (IRT Essentials)

Source

Not published

Source

Product details

Prancer RTSM

Study fit: sponsors and CROs with complex dosing or adaptive designs who want an RTSM specialist with supply forecasting

4G Clinical is an RTSM specialist: Prancer covers randomization, resupply and direct-to-patient shipping, and 4C Supply adds portfolio-level forecasting. It publishes a SOC 2 Type 2 report and a Part 11 statement, and says it has supported more than 1,000 studies. It has no EDC or eCOA of its own, so plan for integrations.

Randomization and blinding

4G names stratification, cohort-specific logic, variable blocks and minimization, with versioned logic that protects blinding and handles re-randomization.

Source
Trial supply management

Prancer handles dispensing and resupply with buffer-to-predictive forecasting and 4C Supply scenario modeling; direct-to-patient shipping was added in April 2020 (4G blog).

Source
Study build speed and mid-study changes

4G says its NLP-based build takes under four weeks, with specification sign-off to go-live in as little as 13 calendar days, and changes made without impacting study progress.

Source
Integrations and platform

4G documents connections to EDC, CTMS, depot and logistics systems and data warehouses, but has no EDC or eCOA of its own and we found no public API reference.

Source
Compliance and security evidence

The trust center reports a SOC 2 Type 2 report for the 12 months ending 31 August 2026 and states compliance with 21 CFR Part 11 and EU Annex 11.

Source
Track record

4G says it has evolved to support more than a thousand studies worldwide.

Source
Pricing model
Not publishedSource
Headquarters
Massachusetts-based (state only; street address not checked)Source

Less suitable for buyers who want RTSM, EDC and eCOA from one vendor

View the 4G Clinical profile Visit website

Almac IXRS 3

Study fit: sponsors who also use Almac for clinical packaging and distribution and want IRT, forecasting and logistics from one group

Almac's IXRS 3 links to Almac's own clinical supply, SupplyWise forecasting and distribution services, and supports direct-to-patient workflows. Almac reports about 2,000 trials run on IXRS. Its public pages give no build timeline, name few randomization methods and show no named security certification.

Randomization and blinding

Almac describes simple to complex adaptive designs with enrollment caps, cohorts and blinding protection, but does not name allocation methods.

Source
Trial supply management

IXRS 3 documents resupply strategy, expiry and depot management, Almac's SupplyWise integrates demand forecasting with the IRT, and an Almac datasheet (Clinical Leader, August 2025) describes direct-to-patient workflows.

Source
Study build speed and mid-study changes

Almac describes a controlled-agile build with visual requirements tools, but publishes no build timeline or mid-study change process.

Source
Integrations and platform

Almac lists pre-built connectors and REST, SOAP and secure file integrations with EDC, CTMS, clinical supplies and central labs, but has no EDC or eCOA of its own.

Source
Compliance and security evidence

Almac states its IXRS University training module is validated and 21 CFR Part 11 compliant; we found no named ISO 27001 or SOC 2 attestation for Clinical Technologies.

Source
Track record

Almac's media kit reports 2,000 clinical trials and over 2 million patients on IXRS, in more than 85 countries (undated kit).

Source
Pricing model
Not publishedSource
Headquarters
Almac House, Craigavon, Northern IrelandSource

Less suitable for buyers who need a published build timeline or a named security certification

View the Almac profile Visit website

Endpoint Clinical RTSM

Study fit: sponsors who want an RTSM specialist with self-service study changes and central pharmacy workflows

Endpoint Clinical is an RTSM specialist with two platforms: PULSE, with 20+ self-service modules, and the newer Elosity, which claims 2-6 week study setup and adds direct-to-patient shipping. Its Bluefin product adds supply forecasting. Public pages name few randomization methods, and the only named attestation is SOC 2 Type II.

Randomization and blinding

Endpoint cites complex protocols, dosing strategies, adaptive designs and patient rollover, but its product pages do not name specific allocation methods.

Source
Trial supply management

Elosity adds direct-to-patient delivery, site-to-site shipments, central pharmacy workflows and pooling, and Endpoint's Bluefin product provides AI-driven supply forecasting.

Source
Study build speed and mid-study changes

Elosity claims a 2-6 week study setup and version-tracked quick changes without interrupting live studies; PULSE offers 20+ self-service modules.

Source
Integrations and platform

Endpoint describes pre-built, API-based integrations with EDC, eCOA, eConsent and CTMS, but names no specific systems and has no EDC or eCOA of its own.

Source
Compliance and security evidence

Endpoint holds a SOC 2 Type II attestation (Prescient Assurance); we found no product-specific Part 11 or Annex 11 statement beyond a general FAQ.

Source
Track record

Endpoint reports 2,000+ studies, 1M+ patients and 90+ countries.

Source
Pricing model
Not publishedSource
Security certifications
SOC 2 Type II, attested by Prescient AssuranceSource
Headquarters
8045 Arco Corporate Drive, Raleigh, NCSource

Less suitable for buyers who want RTSM unified with an EDC from the same vendor

View the Endpoint profile Visit website

Medidata RTSM

Study fit: sponsors already on Rave EDC who want randomization and supply in the same system

Medidata RTSM is unified with Rave EDC, so randomization and dispensing data do not need reconciling between two systems. Its fact sheets document block, stratified and dynamic allocation, supply forecasting, direct-to-patient shipping and post-go-live changes with little to no downtime. Pricing is not published.

Randomization and blinding

A Medidata fact sheet lists pre-validated permuted block and dynamic allocation, stratification, cohort management, titration and a randomization simulator (fact sheet dated May 2019).

Source
Trial supply management

The current fact sheet documents buffer and predictive supply schemes, forecasting that simulates future patient needs, direct-to-patient shipments and drug pooling across studies.

Source
Study build speed and mid-study changes

Medidata states a 2-3 week study build, and Edit Live Design allows post-go-live changes for protocol amendments (the 2024 fact sheet adds 'little to no downtime').

Source
Integrations and platform

RTSM is unified with Rave EDC on the Medidata Platform and uses a pre-validated two-way integration with large depot vendors.

Source
Compliance and security evidence

Medidata lists an ISO 27001:2022 certificate and a SOC 2+ Type II audit, and says its position statements cover 21 CFR Part 11 and EU Annex 11 (the statements sit behind a customer login).

Source
Track record

The RTSM page cites 124 countries supported and about 16,000 patients a month.

Source
Pricing model
No prices published; the Patient Cloud service descriptions publish contract terms (devices on a rental basis, caps on fee adjustments, early-termination fees)Source
Security certifications
ISO 27001:2022, ISO 27017:2015, ISO 27018:2019, ISO 27701:2019, SOC 2+ Type IISource
Headquarters
New York, NY (350 Hudson Street, per ISO certificate)Source

Less suitable for teams that need published prices or a self-serve contract for a single small study.

View the Medidata profile Visit website

Signant SmartSignals RTSM

Study fit: sponsors who want RTSM, supply forecasting and eCOA from one vendor

Signant's RTSM sits next to its SmartSignals Supplies forecasting and inventory software and its eCOA, with direct-to-patient dispensing and pooling across studies. Signant reports 2,000+ RTSM studies and builds in as little as three weeks to UAT. Its public RTSM pages do not name randomization methods or a security certification.

Randomization and blinding

Signant mentions emergency unblinding and support for any protocol design or randomization scheme, but does not name allocation methods.

Source
Trial supply management

Signant documents direct-to-patient dispensing, cross-study pooling, shelf-life optimization and a Forecasting and Planning module in SmartSignals Supplies.

Source
Study build speed and mid-study changes

Signant states new builds in as little as three weeks from requirements sign-off to UAT and AI-assisted impact assessment for amendments, but does not claim changes without downtime.

Source
Integrations and platform

The RTSM connects to Signant's own eCOA and supplies software, third-party EDC and manufacturing systems, and offers RTSM APIs for near real-time data.

Source
Compliance and security evidence

Signant states that its SmartSignals Supplies inventory transaction history is 21 CFR Part 11 compliant; we found no named ISO 27001 or SOC 2 attestation.

Source
Track record

A March 2026 Signant brochure reports 2,000+ RTSM studies in 90+ countries and 600+ sponsors and CROs as customers.

Source
Pricing model
Not publishedSource

Less suitable for teams that need published pricing or a published security certificate

View the Signant profile Visit website

Suvoda RTSM

Study fit: oncology, CNS and rare disease sponsors who want IRT alongside eCOA, eConsent and patient payments on one platform

Suvoda runs its RTSM on one platform with eCOA, eConsent and Greenphire patient payments, and offers pre-built API integrations with major EDCs. It publishes the shortest build claim on this list (kickoff to UAT in as little as two weeks, footnoted as preliminary testing) and an annual SOC 2 Type 2 audit for RTSM. Its public pages name stratification and adaptive designs but not minimization.

Randomization and blinding

Suvoda lists adaptive randomization, stratification, cohort and dose management and blinding management, but its public pages do not name minimization or dynamic allocation.

Source
Trial supply management

The RTSM page lists drug supply forecasting, direct-to-patient shipping, temperature excursion management, and accountability, returns and destruction.

Source
Study build speed and mid-study changes

Suvoda states kickoff to UAT in as little as two weeks (footnoted as preliminary testing), and permissioned users can make common post-go-live changes without a change order.

Source
Integrations and platform

Suvoda reports integrations with more than 100 eClinical systems, standardized pre-built API integrations with top EDC providers and a REST API.

Source
Compliance and security evidence

Suvoda says its RTSM adheres to 21 CFR Part 11 and that it maintains SOC 2 Type 2 compliance; its certifications page confirms an annual SOC 2 Type 2 audit for RTSM.

Source
Track record

Suvoda reports 6,000+ trials and 115+ countries supported.

Source
Pricing model
Not publishedSource
Security certifications
Annual SOC 2 Type 2 audit for RTSM, eCOA and eConsent; ISO 27001 for Greenphire payments productsSource

Less suitable for buyers who need minimization or dynamic allocation confirmed in public material before a demo

View the Suvoda profile Visit website

Veeva RTSM

Study fit: sponsors standardizing on the Veeva Clinical Platform who want RTSM connected to Veeva EDC, eCOA and CTMS

Veeva RTSM lists a broad set of randomization schemas and productized connections to Veeva EDC, eCOA and CTMS, and a top-20 biopharma chose it as its enterprise standard in fiscal 2026. Public material does not describe direct-to-patient shipping or a dedicated forecasting tool, and no build timeline is published.

Randomization and blinding

Veeva lists static, stratified, dynamic/minimization, forced and adaptive schemas, re-randomization, capping and sentinel dosing.

Source
Trial supply management

Veeva documents threshold, predictive and just-in-time resupply with expiry buffers and accountability, but no direct-to-patient shipping or separate forecasting tool.

Source
Study build speed and mid-study changes

Authorized users can switch on cohorts and change limits mid-study, and Veeva says design-change amendments often take days rather than weeks; no initial build timeline is published.

Source
Integrations and platform

Productized connections send data to Veeva EDC, eCOA and DQS and take site data from Veeva CTMS, and the brief cites third-party EDC and shipping-provider connections.

Source
Compliance and security evidence

Veeva's trust page lists ISO 27001 audits and a SOC 2 Type II report, but we found no RTSM-specific Part 11 or Annex 11 statement.

Source
Track record

Veeva reports that a top-20 biopharma selected Veeva RTSM as its enterprise standard (fiscal 2026); no total study or customer count for RTSM is published.

Source
Pricing model
Not publishedSource
Security certifications
ISO 27001, ISO 27017, ISO 27018 controls audited yearly; SOC 2 Type II report; ISO 9001Source
Headquarters
4280 Hacienda Drive, Pleasanton, CA 94588Source

Less suitable for teams that need published prices, or a stand-alone EDC with a short single-study contract.

View the Veeva profile Visit website

YPrime IRT

Study fit: sponsors with complex randomization schemes, including minimization, who may also use YPrime eCOA

YPrime names more randomization methods than any other vendor here, from permuted blocks to Pocock-Simon minimization, and publishes short build times. Its public IRT page does not describe supply forecasting or direct-to-patient shipping, and we found no named security certification.

Randomization and blinding

YPrime names permuted block and stratified randomization, dynamic allocation and minimization (Pocock and Simon), stratum caps and conditional re-randomization.

Source
Trial supply management

The IRT page covers inventory, orders, resupply, kit replacement and depot rules, but does not describe supply forecasting or direct-to-patient shipping.

Source
Study build speed and mid-study changes

YPrime cites build to go-live in under four weeks for an early-phase oncology trial, about a week for the simplest designs, and self-service routine changes that take effect immediately.

Source
Integrations and platform

YPrime documents integrations with EDC, eCOA, eConsent, CTMS, labs, distribution systems and data lakes, and runs its own eCOA.

Source
Compliance and security evidence

YPrime's trust page lists 21 CFR Part 11, GDPR and HIPAA compliance, but we found no ISO 27001 or SOC 2 attestation.

Source
Track record

YPrime reports 55,000+ sites and 300,000+ patients supported and 20+ years of IRT work, but publishes no study count.

Source
Pricing model
Not publishedSource
Security certifications
ISO 27001 certification in progress (target 2027)Source

Less suitable for teams that need a self-service builder, published pricing or a current ISO 27001 certificate

View the YPrime profile Visit website

How we compare this software

This guide compares 8 products across the same feature topics. Each statement describes what the available public sources document, including limitations and study requirements.

Scope: Sponsors and CROs choosing an RTSM/IRT system to randomize participants and manage investigational product supply in interventional trials. Site-side pharmacy tools and stand-alone supply planning software are out of scope.

  • Randomization and blinding
  • Trial supply management
  • Study build speed and mid-study changes
  • Integrations and platform
  • Compliance and security evidence
  • Track record

A vendor’s published claim is not independent confirmation that a product will meet your study’s needs. Check deployment, validation, integrations and commercial terms with the vendor.

Outside this comparison: Calyx (calyx.ai now redirects to perceptive.com) and IQVIA's Cenduit IRT were considered but not included in this comparison; this comparison covers eight vendors with public documentation available for review.

Read the comparison method

Questions about RTSM / IRT software

What is the difference between RTSM and IRT?

They describe the same kind of system. IRT (interactive response technology) is the older name, from phone and web randomization systems; RTSM (randomization and trial supply management) names what the system does: assign participants to treatment and keep sites or patients supplied with blinded study drug.

How long does it take to build an RTSM study?

Vendors on this list publish build claims of roughly two to six weeks: Suvoda says kickoff to UAT in as little as two weeks (preliminary testing), Medidata a 2-3 week build, Signant about three weeks to UAT, 4G Clinical under four weeks and Endpoint's Elosity 2-6 weeks. These are vendor figures, so ask for timelines on studies like yours.

Which RTSM systems support direct-to-patient shipping?

Medidata, 4G Clinical, Suvoda, Endpoint (Elosity), Signant and Almac publicly document direct-to-patient shipping. The public RTSM pages of YPrime and Veeva do not describe it, so confirm it in a demo if your study needs it.

How much does an RTSM system cost?

None of the eight vendors publishes prices. Large sponsors often buy RTSM study by study, as Veeva noted in its fiscal 2026 results call. Ask for a quote that separates the initial build, monthly hosting and the cost of mid-study changes.